株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の樹状細胞癌ワクチン市場・臨床試験の見通し

Global Dendritic Cell Cancer Vaccine Market and Clinical Trials Outlook 2023

発行 KuicK Research 商品コード 322277
出版日 ページ情報 英文 170 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.19円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
世界の樹状細胞癌ワクチン市場・臨床試験の見通し Global Dendritic Cell Cancer Vaccine Market and Clinical Trials Outlook 2023
出版日: 2017年06月09日 ページ情報: 英文 170 Pages
概要

当レポートでは、世界の樹状細胞癌ワクチン市場について調査分析し、市場概要、評価、臨床パイプライン、上市製品、将来の成長機会など、体系的な情報を提供しています。

第1章 オンコロジーにおける樹状細胞ワクチンの登場

第2章 樹状細胞への分類

第3章 樹状細胞による免疫反応の調節

  • 抗原出現
  • 抗原の積み重ね
  • 樹状細胞源・サブセット
  • 成熟へ
  • 刺激による成熟
  • リンパ節への移動
  • ワクチン接種の精度
  • 臨床結果
  • 品質管理
  • 免疫モニタリング

第4章 樹状細胞ワクチンの準備

  • CD4 T・CD8 T細胞の交差提示
  • 原位置 (in situ) での補充、成熟、投入戦略
  • NKT細胞の活性化戦略

第5章 その他の治療法との樹状細胞ワクチンの評価

  • 樹状細胞癌ワクチンとモノクローナル抗体
  • 樹状細胞癌ワクチンとペプチドベースの癌ワクチン
  • 樹状細胞癌ワクチンとサイトカンベースの癌ワクチン
  • 樹状細胞癌ワクチンと抗体薬剤の共役ベースの癌ワクチン

第6章 樹状細胞癌ワクチン市場と臨床考察

  • 樹状細胞癌ワクチン接種に関する動向
  • 樹状細胞癌ワクチンパイプラインの概要

第7章 樹状細胞癌ワクチン成長の底流

第8章 樹状細胞癌ワクチンの課題

第9章 将来の見通し

第10章 樹状細胞癌ワクチンの臨床パイプライン:企業別、適応別、相別

  • 研究
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相

第11章 上市済みの樹状細胞ワクチンの臨床考察

第12章 競合情勢

  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • Bellicum Pharmaceuticals
  • Creagene
  • DanDrit Biotech
  • DCPrime
  • Dendreon Corporation
  • Elios Therapeutics
  • ImmunoCellular Therapeutics
  • Immunicum
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • Glaxo Smith Kline
  • ImmunoCellular Therapeutics
  • SOTIO
  • Tella Incorporation
  • Theravectys
  • Vaxil BioTherapeutics

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

“Global Dendritic Cell Cancer Vaccine Market and Clinical Trials Outlook 2023” report gives comprehensive insight on various clinical and non-clinical advancements in the global dendritic cell cancer vaccine market. In recent years, dendritic cell cancer vaccines have emerged as new growth frontier for the companies involved in the research and development of drugs for the treatment of cancer. As per report findings, currently there are 53 dendritic cell cancer vaccines in clinical pipeline. Most of the dendritic cell cancer vaccines are in preclinical phase followed by phase-II clinical trials.

“Global Dendritic Cell Cancer Vaccine Market and Clinical Trials Outlook 2023” Highlights:

  • Global Dendritic Cell Cancer Vaccine Market Overview
  • Assessment of Dendritic Vaccines with Other Therapeutic Regimens
  • Global Dendritic Cell Vaccines Clinical Pipeline by Company, Indication and Phase
  • Marketed Dendritic Cell Vaccines Clinical Insight
  • Dendritic Cells Mechanizing Immune Response
  • Future Growth Opportunities

Cancer is the leading cause of death worldwide and with around 18 million to 20 million new cases emerging every year, it takes heavy toll on people life and property. The governments across the globe along with private sectors have invested heavily in cancer therapeutics, which will be on the rising curve given the factors that abnormally increase the concentration of carcinogens in the atmosphere like vehicular emissions, environmental degradation coupled with drastic lifestyle changes like leading a sedentary life, lack of exercise etc.

Meanwhile, the conventional cancer therapeutics has but failed to yield desired result. During chemotherapy or radiation therapy or hormonal treatments which are the working horse of the cancer treatment besides tumor cells, normal surrounding cells are also killed. The necrosis factors associated with the dying normal cells signals inflammatory response to kick in and take the immune system on hyper drive killing tumor cells as well as normal, healthy adjoining cells as a collateral damage. This brings out the biggest irony, that the body instead of fighting off the cancer becomes susceptible to plethora of other life-threatening abnormalities causing high morbidity.

Dendritic cell cancer vaccines have created a niche for themselves in the cancer market, because they enjoy some inherent biochemical properties which could only be envy by their peers. They are the best known antigen presenting cells, as their task is to bind to the antigen peptides with MHC molecules and activate CD4+ T cells or CD8+ T cells to elicit the desired innate and adoptive immunity. Their action with MHC molecule offers dendritic cells, the prerequisite specificity in targeting the tumor associated antigens of various cancer types and its sub-types. This has enabled dendritic cell cancer vaccines to offer a wide domain of therapeutic action.

The recent advancement in in situ dendritic cell production from its progenitor cells, its maturation enabling processes and its delivery techniques has added to their advantage. They are also known to generate memory T cells which could produce a heightened secondary immune response for future encounters with the tumor cells in case of tumor progression. As cancer cells are known to evade immune response by triggering regulatory T cells suppressing the immune system, dendritic cells come to the rescue as it antagonistically acts on immune checkpoint inhibitors like CLAT4 and CD25 mediated immune pathways, thereby breaking the host's immune tolerance.

As dendritic cells are found to have a modulatory effect on almost all the parameters of the immune system, all other types of cancer vaccines are found to be administered in conjugation with dendritic cells cancer vaccine to have a synergistic effect on immune system against tumor growth. With further advancement in immunological studies, dendritic cells cancer vaccine will have a driving effect on cancer therapeutics which will have a lion's share on cancer vaccine market.

Even though some technical concerns existed regarding in situ production of dendritic cells due to its low concentration in peripheral tissues, it has been successfully overcome with engineered dendritic cells which could now be produced in large number for mass scale vaccination programs. Simultaneous administration of regulating factors which facilitate dendritic cell survival and immune-modulator function holds the key for increased efficiency of cancer vaccine based on dendritic cell, the superspecialised sentinels of cancer immunotherapy, the title it truly deserves.

Table of Contents

1. Advent of Dendritic Vaccine in Oncology

2. Cataloging towards Dendritic Cells

3. Dendritic Cells Mechanizing Immune Response

  • 3.1. Antigen Appearance Leads to Cellular Immune Responses
  • 3.2. Stacking of Distinct Antigens over Dendritic Cells
  • 3.3. Dendritic Cells Source and Subsets
  • 3.4. Trail towards Maturation
  • 3.5. Stimulation Initiates Maturation
  • 3.6. Migration to Lymph Node
  • 3.7. Precision of Dendritic Cells Vaccination
  • 3.8. Illustrations of Clinical Results among Varied Cancer
  • 3.9. Quality Control
  • 3.10. Immune Monitoring

4. Equipping Dendritic Cell Vaccines

  • 4.1. Cross Presentation of CD4 T-CD8 T Cells
  • 4.2. Strategies to Recruit, Mature and Load Dendritic Cells In Situ
  • 4.3. Strategies to Activate NKT Cells

5. Assessment of Dendritic Vaccines with Other Therapeutic Regimens

  • 5.1. Dendritic Cell Cancer Vaccine and Monoclonal Antibodies
  • 5.2. Dendritic Cell Cancer Vaccine and Peptide Based Cancer Vaccine
  • 5.3. Dendritic Cell Cancer Vaccine and Cytokine Based Cancer Vaccine
  • 5.4. Dendritic Cell Cancer Vaccine and Antibody Drug Conjugate Based Cancer Vaccine

6. Dendritic Cell Cancer Vaccine Market and Clinical Insight

  • 6.1. Some Trends Involving Dendritic Cells Cancer Vaccination
  • 6.2. Dendritic Cell Cancer Vaccine Pipeline Overview

7. Undercurrents of Dendritic Cancer Vaccine Growth

8. Challenging Milieu for Dendritic Cancer Vaccine

9. Prospective Trajectories for Future

10. Dendritic Cell Vaccines Clinical Pipeline by Company, Indication and Phase

  • 10.1. Research
  • 10.2. Preclinical
  • 10.3. Clinical
  • 10.4. Phase I
  • 10.5. Phase I/II
  • 10.6. Phase II
  • 10.7. Phase II/III
  • 10.8. Phase III

11. Marketed Dendritic Cell Vaccines Clinical Insight

  • 11.1. Sipuleucel-T (Provenge)
  • 11.2. Dendritic Cell Vaccine (CreaVax-HCC,CreaVax-PC and CreaVax-RCC)
  • 11.3. Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

12. Competitve Landscape

  • 12.1. 3M Company
  • 12.2. Activartis
  • 12.3. Argos Therapeutics
  • 12.4. Batavia Bioservices
  • 12.5. Bellicum Pharmaceuticals
  • 12.6. Creagene
  • 12.7. DanDrit Biotech
  • 12.8. DCPrime
  • 12.9. Dendreon Corporation
  • 12.10. Elios Therapeutics
  • 12.11. ImmunoCellular Therapeutics
  • 12.12. Immunicum
  • 12.13. Kiromic
  • 12.14. Medigene
  • 12.15. Merck
  • 12.16. Northwest Biotherapeutics
  • 12.17. Glaxo Smith Kline
  • 12.18. ImmunoCellular Therapeutics
  • 12.19. SOTIO
  • 12.20. Tella Incorporation
  • 12.21. Theravectys
  • 12.22. Vaxil BioTherapeutics

List of Figures:

  • Figure 1-1: Advantages of Dendritic Cell Cancer Vaccine
  • Figure 2-1: Classification of Dendritic Cells
  • Figure 3-1: Principle of Dendritic Cell Cancer Immunotherapy
  • Figure 3-2: The Key Players Intricately Involved in Antigen Presentation and Immune Response Machinery
  • Figure 3-3: Process of Antigen-loading
  • Figure 3-4: Major Life Cycle Events of a Dendritic Cell
  • Figure 3-5: A Diagrammatic Representation of Dendritic Cell Plasticity
  • Figure 3-6: Action of Dendritic Cells on the Various Cancer Forms
  • Figure 4-1: The Arsenals in the Inventory of Dendritic Cells
  • Figure 5-1: Working Principle Targeted By Dendritic Cells and Monoclonal Antibodies
  • Figure 5-2: Working Principle Targeted by Dendritic Cells and Peptide Cancer Vaccines
  • Figure 5-3: Working Principle Targeted by Dendritic Cells and Cytokine Cancer Vaccine
  • Figure 5-4: Working Principle Targeted By Dendritic Cells and Antibody-Drug Conjugates Cancer Vaccines
  • Figure 6-1: Recent Trends in Dendritic Cell Vaccine
  • Figure 6-2: Global - Dendritic Cell Cancer Vaccine Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 6-3: Global - Dendritic Cell Cancer Vaccine Clinical Pipeline by Phase (Number), 2017 till 2023
  • Figure 6-4: Global andndash; Suspended Dendritic Cell Vaccine in Clinical Pipeline by Phase (%), 2017 till 2023
  • Figure 6-5: Global andndash; Suspended Dendritic Cell Vaccine in Pipeline by Phase (Number), 2017 till 2023
  • Figure 7-1: Factors Driving Dendritic Cell Cancer Vaccine
  • Figure 8-1: Challenges for Dendritic Cell Cancer Vaccine
  • Figure 12-1: Argos Therapeutics- Clinical Pipeline
  • Figure 12-2: Bellicum Pharmaceuticals Clinical Pipeline
  • Figure 12-3: DCPrime Clinical Pipeline
  • Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 12-5: Immunicum Clinical Pipeline
  • Figure 12-6: Medigene Clinical Pipeline
  • Figure 12-7: Northwest Biotherapeutics Clinical Pipeline
  • Figure 12-8: SOTIO Clinical Pipeline
Back to Top